<DOC>
	<DOCNO>NCT01565538</DOCNO>
	<brief_summary>Both pemetrexed erlotinib second-line treatment option patient advance non-small cell lung cancer . It controversial whether necessary detect epidermal growth factor receptor ( EGFR ) mutation status EGFR-targeted therapy failure standard chemotherapy . The role EGFR gene copy number predictive marker remain controversial . Therefore , investigate efficacy erlotinib pemetrexed second-line therapy treat patient EGFR wild-type EGFR FISH-positive advance lung adenocarcinoma .</brief_summary>
	<brief_title>Erlotinib Versus Pemetrexed Second-Line Therapy Treating Patients With Advanced Lung Adenocarcinoma</brief_title>
	<detailed_description>Standard first-line treatment advanced-stage non-small cell lung cancer ( NSCLC ) usually consist platinum-based doublet chemotherapy , progression ultimately occur patient . Second-line treatment option available patient suffer failure first-line treatment include chemotherapy ( docetaxel pemetrexed ) target therapy . Epidermal growth factor receptor tyrosine kinase inhibitor ( EGFR-TKIs ) show great efficacy patient advance NSCLC EGFR mutation . High EGFR gene copy number associate great sensitivity prolong progression-free survival NSCLC EGFR-TKIs . This phase II study design assess efficacy safety erlotinib compare pemetrexed second-line treatment EGFR wild-type EGFR FISH-positive lung adenocarcinoma .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Histologically cytologically confirm Lung adenocarcinoma Wldtype EGFR Stage IIIB/IV Failure prior chemotherapy Life expectancy 3 month Tissue sample desire genomic study Age â‰¥ 18 year Performance status ( WHO ) &lt; 3 Adequate bone marrow function ( absolute neutrophil count &gt; 1000/mm^3 , platelet count &gt; 100000/mm^3 , hemoglobin &gt; 9gr/mm^3 ) Adequate liver ( bilirubin &lt; 1.5 time upper limit normal SGOT/SGPT &lt; 2 time upper limit normal ) renal function ( creatinine &lt; 2mg/dl ) Presence twodimensional measurable disease . The measurable disease irradiate Informed consent Have previously receive pemetrexed TKIs Other concurrent uncontrolled illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Non-small-cell lung cancer</keyword>
	<keyword>Adenocarcinoma</keyword>
	<keyword>EGFR gene mutation</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Pemetrexed</keyword>
	<keyword>Erlotinib</keyword>
</DOC>